Silexion Therapeutics Corp
moringaac.comWhat Do They Do?
Develops experimental treatments that silence KRAS mutations in cancer cells, focusing on pancreatic cancer.
10-K for FY2025, filed Mar 17, 2026We are a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for…View ↗
Our proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular…View ↗
We are currently focused on treatment of non-resectable locally advanced pancreatic cancer (LAPC) patients which bear a KRAS mutation. LAPC…View ↗
How Do They Make Money?
$155K
-
10-K for FY2025, filed Mar 17, 2026
$155K ↗
Do Revenues Turn Into Profits?
No. It lost $11.9M in FY2025.
10-K for FY2025, filed Mar 17, 2026
−$11.6MView ↗
10-K for FY2025, filed Mar 17, 2026
−$11.9MView ↗
10-K for FY2025, filed Mar 17, 2026
−$10.8MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$3.6MView ↗
- ▲ +42% (Loss)
- vs −$2.5M in Q2 FY2025
-
Aug 21, 2026
Nasdaq issued a delisting notice over a shareholders’ equity deficiency
The company intends to appeal; an unsuccessful appeal could lead to trading suspension and removal from Nasdaq.
Sources
8-K, filed Aug 21, 2026
On August 18, 2026, Silexion Therapeutics Corp, a Cayman Islands exempted company (the “Company”, “we”, “us” or “our”) received a delisting…View ↗
Who Do They Compete With?
Competes with Amgen, Bristol-Myers Squibb, Revolution Medicines, Chengdu Hyperway, GenFleet, Erasca, Jacobio, AstraZeneca, Pfizer, BeOne, Lilly, Chugai, Roche, Astellas, BridgeBio Oncology, Adlai Nortye, Jiangsu HengRui, 280Bio, Treeline Biosciences, and Alterome Therapeutics
10-K for FY2025, filed Mar 17, 2026There are a large number of companies developing or marketing treatments for cancer, including major biotechnology and pharmaceutical…View ↗
Loading...
